InVivo Therapeutics Announces Appointment of Ann Merrifield as Lead Director

- Committee Chairs Announced for Nominating and Corporate Governance, Compensation, and Audit Committees -

CAMBRIDGE, Mass.--(BUSINESS WIRE)--InVivo Therapeutics Holdings Corp. (NVIV) today announced the Company's Board of Directors has appointed independent director Ann Merrifield to the newly created position of Lead Director. The Lead Director will serve as a liaison between the Chairman and non-management directors, chair all executive sessions, and work with the Chairman on meeting agendas and time schedules for the Board of Directors.

"Ann Merrifield's deep industry knowledge and expertise has proven to be invaluable since joining the Board of Directors in November 2014"
"Ann Merrifield's deep industry knowledge and expertise has proven to be invaluable since joining the Board of Directors in November 2014," said Mark Perrin, InVivo's Chief Executive Officer and Chairman. "Her proven leadership capabilities make her an excellent choice for Lead Director, and I look forward to working closely with her."

The Company's Board of Directors also approved splitting the Governance, Nominating, and Compensation Committee into two committees: the Nominating and Corporate Governance Committee and the Compensation Committee. Ann Merrifield has been appointed as the new Chairwoman of the Nominating and Corporate Governance Committee. Kenneth DiPietro will serve as Chairman of the newly created Compensation Committee, and John McCarthy, Jr. will continue to serve as the Audit Committee Chairman.

About InVivo Therapeutics

InVivo Therapeutics Holdings Corp. is a research and clinical-stage biomaterials and biotechnology company with a focus on treatment of spinal cord injuries. The company was founded in 2005 with proprietary technology co-invented by Robert Langer, Sc.D., Professor at Massachusetts Institute of Technology, and Joseph P. Vacanti, M.D., who then was at Boston Children's Hospital and who now is affiliated with Massachusetts General Hospital. In 2011, the company earned the David S. Apple Award from the American Spinal Injury Association for its outstanding contribution to spinal cord injury medicine. In 2015, the company's investigational Neuro-Spinal Scaffold received the 2015 Becker's Healthcare Spine Device Award. The publicly-traded company is headquartered in Cambridge, MA. For more details, visit www.invivotherapeutics.com.

Contacts

InVivo Therapeutics Holdings Corp.
Brian Luque, 617-863-5535
Investor Relations
[email protected]

Suggested Articles

Half of patients in an early trial of Allogene's off-the-shelf CAR-T cells for lymphoma who received a higher dose of its antibody ALLO-647 responded.

Takeda is tossing out a Shire pipeline med after it couldn't find a buyer.

Ipsen's new hire arrives at a company reeling from a torrent six months that have crushed hopes for its $1 billion bet on a rare disease drug.